Astrazeneca (AZN) Asset Utilization Ratio (2016 - 2026)

Astrazeneca has reported Asset Utilization Ratio over the past 16 years, most recently at 0.53 for Q1 2026.

For Q1 2026, Asset Utilization Ratio rose 1.35% year-over-year to 0.53; the TTM value through Mar 2026 reached 0.53, up 1.35%, while the annual FY2025 figure was 0.54, 2944.64% up from the prior year.
Asset Utilization Ratio for Q1 2026 was 0.53 at Astrazeneca, up from 0.51 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 0.95 in Q4 2023 and troughed at 0.44 in Q2 2022.
A 5-year average of 0.56 and a median of 0.51 in 2025 define the central range for Asset Utilization Ratio.
On a YoY basis, Asset Utilization Ratio climbed as much as 110.04% in 2023 and fell as far as 45.56% in 2023.
Year by year, Asset Utilization Ratio stood at 0.45 in 2022, then soared by 110.04% to 0.95 in 2023, then tumbled by 45.55% to 0.52 in 2024, then dropped by 0.67% to 0.51 in 2025, then rose by 3.09% to 0.53 in 2026.
Business Quant data shows Asset Utilization Ratio for AZN at 0.53 in Q1 2026, 0.51 in Q4 2025, and 0.51 in Q3 2025.

Peer Comparison